The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Paxlovid (nirmatrelvir + ritonavir)…. read more.
NICE (UK) Nirmatrelvir plus ritonavir is recommended as an option for treating COVID‑19 in adults, only if they: i) do not need supplemental oxygen for COVID‑19 and, ii)… read more.
Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research. The study questions the assumption that Paxlovid’s effectiveness in reducing… read more.
An up-close look at how patients respond to the drug at different times and doses adds nuance to a recent finding that Paxlovid does not work for long… read more.
Researchers from a study of patients treated for acute COVID-19 report that virologic rebound takes place in about 20.8 percent of subjects treated with nirmatrelvir-ritonavir (N-R, Paxlovid) versus… read more.
A Kaiser Permanente study confirms the benefit of nirmatrelvir-ritonavir, also known as Paxlovid, as an early-stage treatment to prevent hospitalization for people with mild to moderate COVID-19, regardless… read more.
The antiviral drug nirmatrelvir plus ritonavir (Paxlovid) was granted Emergency Use Authorization for treating COVID-19 in December 2021. In clinical trials, the antiviral was associated with an 88%… read more.
China’s medical products regulator has given conditional approval for Pfizer’s COVID-19 drug Paxlovid, making it the first oral pill specifically developed to treat the disease cleared in the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
